VOR
Vor Biopharma Inc.
NASDAQ · Healthcare · Biotechnology · US
$25.05
+3.34%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +294.4%
- EBIT
- +60.0%
- EPS
- -19.2%
- Free cash flow
- -23.7%
- Operating cash flow
- -23.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +98.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -43.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026